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ABSTRACT 
Introduction: The treatment of leishmaniasis ischallenging, given the difﬁ culties in drug administration and resistance. 
Therefore, we chose to test the efﬁ cacy of miltefosine combined with pentoxifylline. Methods: Twenty-seven isogenic C57Bl/6 
mice were infected with Leishmania (Leishmania) amazonensis, and equally divided into three groups: miltefosine (200mg/
kg/day), miltefosine (200mg/kg/day) with pentoxifylline (8mg/kg/day), and untreated. Response to treatment was evaluated 
using paw diameter and parasitological criteria. Results: The number of viable Leishmania reduced signiﬁ cantly within the 
miltefosine-pentoxifylline group (p < 0.05). Conclusions: There is hope that a viable treatment exists for Leishmania infection.
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Cutaneous leishmaniasis (CL) is an infectious disease caused 
by different species of protozoa from the genus Leishmania, 
and is observed worldwide. The pathogenesis of CL involves 
a dysregulated immune response with overproduction of 
proinﬂ ammatory cytokines, regulatory cytokines deﬁ ciency, 
and lysis mechanisms by which intracellular parasites escape1,2. 
Unfortunately, therapies for treating Leishmania infection 
remain limited, and pentavalent antimonials have remained 
the drugs of choice for over 60 years. All ﬁ rst and second 
drug choices, including miltefosine, have high toxicity, 
require parenteral use, have high rates of relapse and drug 
resistance, and ultimately lead to treatment failure, especially 
in immunocompromised patients who desperately require 
new therapies3. Miltefosine (hexadecylphosphocholine) is an 
alkylphosphocholine, originally developed for the treatment 
of cancer, which was discovered to possess antifungal, 
antiamoebic, and leishmanicidal activity4,5. The drug exerts its 
cytotoxic effect by interfering with the metabolism of membrane 
phospholipids, altering the composition, permeability, stability, 
and fluidity of the cell membrane, subsequently inducing 
apoptos is3,6. Miltefosine’s mechanism of action also indirectly 
induces immunomodulatory antileishmanial mechanisms by 
increasing production of gamma interferon (IFN-γ), tumor 
necrosis factor alpha (TNF-α), and interleukin 12 (IL-12), 
thereby increasing phagocytosis and inducing an immune 
response biased towards a Th1 proﬁ le7,8.
Similarly, pentoxifylline (a methylxanthine) has been 
investigated in the treatment of CL, based on its inhibition of nuclear 
factor kappa beta (NF-kβ), TNF-α, and intercellular adhesion 
molecule 1 (ICAM-1)8,9, as well as its nephroprotective effect 
when combined with antimonials10. These immunomodulatory 
effects may help to regulating patients’ exacerbated and 
inefficient intracellular immune response to parasites, and 
subsequently reduce tissue inﬂ ammation. Therefore, this study 
aims to examine the combined immunomodulatory effects of 
two oral drugs, by comparing miltefosine-pentoxifylline to 
miltefosine alone.
In this study, we used 27 isogenic C57Bl/6 mice and 
promastigotes of Leishmania (Leishmania) amazonensis 
(MHOM/BR/PH8) from the Dermatomycology Laboratory 
at the University of Brasilia. All mice were born and raised in 
the vivarium of the Faculty of Medicine at the University of 
Brasilia. This species was chosen since it is a model parasite 
that grows easily in culture media, improving study speed and 
viability. While it is not the most prevalent species, Leishmania 
amazonensis is distributed throughout the country, where it 
causes severe clinical manifestations and diffuse cutaneous 
leishmaniasis. No satisfactory treatment has been discovered11.
These experiments were evaluated and approved by the 
ethics committee for animal use in the Institute of Biological 
Sciences of the University (UnBDOC 43044/2010). All animals 
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were inoculated with 107 parasites in metacyclic promastigote 
form, which were injected subcutaneously in the dorsal tissue of 
the right footpad, following the standardized technique4. Thirty 
days after inoculation, the mice were divided according to sex 
(6 females and 21 males) and randomly sorted into 3 groups, 
each group containing 2 females and 7 males. The groups were 
labeled and treated as follows: (M) oral miltefosine (200mg/
kg/day), (M + P) oral miltefosine (200 mg/kg/day) with oral 
pentoxifylline (8mg/kg/day), and (C) no treatment. Oral dosage 
was performed daily for a period of 12 days, using a gavage 
needle. Treatment response was evaluated using the lateral 
diameter of the right paw, lymph culture in Novy-MacNeal-
Nicolle (NNN) media, the methylthiazol tetrazolium (MTT) 
dye colorimetric assay, and visual detection of amastigotes.
We measured the lateral-lateral diameter of the right footpad 
of each mouse, using a Mitutoyo® millimeter caliper, on the 
ﬁ rst (D1), sixth (D6) and twelfth (D12) day of treatment. On 
the thirteenth day (D13), lymph was aspirated from the infected 
paws and cultured in NNN media. Cultures were observed 
daily, under an inverted light microscope at 40× magniﬁ cation, 
to detect the presence of parasites. The MTT test was carried 
out using a limiting dilution assay as previously described12. 
In short, the infected paws of 2 male mice from each group 
were subjected to sterile dissection and trituration in 5ml of 
Schneider’s culture medium, enriched with 20% fetal bovine 
serum. Serial dilution was performed in standard 96 well 
plates. Plates were incubated at 26°C for 4 days, with daily 
observation under an inverted light microscope. At the end of 
that period, plates were subjected to the MTT colorimetric assay, 
as previously described13. Each culture assay was performed 
at the end of treatment (D13) and on D63. On D13, group (C) 
consisted of 7 mice, group (M) 7 mice, and group (M + P 8) 
mice. On D63, group © consisted of 5 mice, group (M) 3 mice, 
and group (M + P 4) mice. 
Statistical analysis: Statistical analysis was performed using 
R 3.0.0 software (R Core Team, 2013).
Ethical considerations: From the original 27 mice, 9 died 
prior to the end of the experiment, mainly due to inﬁ ghting and 
resulting injuries. Six mice per group were considered adequate 
for statistical analysis, and the possibility of animal death had 
been considered at the time of project approval by the Ethics 
Committee (UnB-Doc 43044/2010). 
Paw diameter: Since pad diameter was not normally 
distributed (based on the Shapiro Wilk and Kolmogorov-
Smirnov tests), we used the Kruskal-Wallis test (using a chi-
square distribution) to analyze the three groups’ response to 
treatment. Our analysis found that on D1, the treatment effect 
was not signiﬁ cant (p = 0.06). However, the treatment effect 
on D6 and D12 was signiﬁ cant (p < 0.01, p < 0.01). Since the 
sample size was small, we tested the suitability of the Kruskal-
Wallis test using Monte Carlo tests. Unfortunately, we were 
unable to process a sample calculation for each variable in the 
analysis. Although the p-values were different between the 
two methods, the inferences were always consistent, so we 
concluded that use of the asymptotic method did not cause bias 
in the inference.
Since the Kruskal-Wallis test found no difference between 
(M) and (M + P) on D6 and D12, we investigated the differences 
in pairs, using the Wilcoxon test to analyze the groups head-to-
head. Treatment with both (M) and (M + P) signiﬁ cantly reduced 
paw diameter compared to the control group, although neither 
group was found to be superior (Figure 1). The respective 
p-values are shown on Table 1. Dunn's posttest was applied 
after the above analysis, and the same inferences remained.
MTT colorimetric assay: The absorbance values obtained 
from the ﬁ rst row of wells (line A) of the plates (corresponding 
to the undiluted Leishmania concentration from the paws) were 
used for comparing the groups, using the Wilcoxon test. Our 
results (Figure 2, Table 1) indicate that there was a signiﬁ cantly 
lower concentration of Leishmania in the (M + P) group, 
compared to the (M) group.
Analysis of cultures: Cultures obtained on D13 were positive 
in all 6 samples from group (C), indicating the presence of 
infection. In group (M), 1 of 6 cultures was positive, and in 
group (M + P), 2 of 6 were positive. Fisher’s t-test only detected 
a signiﬁ cant difference between group (C) and (M) (Table 1).
Analysis of slides: Parasites could only be detected visually 
in the control group (C). All slides from the other groups showed 
no signs of parasites. 
We chose not to use N-methyl glucamine (the ﬁ rst line 
of treatment for Leishmania infection), since we know that 
miltefosine has the same efﬁ cacy in Leishmania amazonensis4, 
and our goal was to test whether a combination of oral drugs 
would provide a better response to treatment. When we analyzed 
the paw diameters, we adopted a signiﬁ cance (alpha) level of 
5%, and both treatment groups (M, M + P) were signiﬁ cantly 
smaller (p < 0.05) than group (C) on D6 and D12. However, 
there was no signiﬁ cant difference between the two treatment 
groups, and thus there is no evidence that either is superior. 



























FIGURE 1 - Paw diameter over time. Paw diameters were 
measured at three time points (D1, D6, and D12). D1 represents 
diameters before initiating treatment, while D6 and D12 represent 
diameters on the sixth and on the twelve day of treatment. 
M: miltefosine; M+P: miltefosine plus pentoxifylline; C: control.
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TABLE 1 - Analysis of experimental parameters.
Parameter of analysis Group C Group M Group M + P Time Groups Average number* p-value
Diameter of the paws (mm) 3.444 ± 0.302 2.855 ± 0.254 2.855 ± 0.194 D6 C vs M  <0.01
     C vs M + P 7.33 <0.01
     M vs M + P  0.92
 3.742 ± 0.315 2.766 ± 0.176 2.733 ± 0.124 D12 C vs M  <0.01
     C vs M + P 7.33 <0.01
     M vs M + P  0.65
Absorbance of A line 1.074 ± 0.198 0.406 ± 0.103 0.221 ± 0.110 D13 C vs M  <0.01
     C vs M + P 7.33 <0.01
     M vs M + P  <0.01
 1.446 ± 0.146 0.381 ± 0.045 0.182 ± 0.036 D63 C vs M  <0.01
     C vs M + P 4 <0.01
     M vs M + P  <0.01
Positive cultures (n) 6 1 2 D13 C vs M  0.01
     C vs M + P 7.33 0.06
     M vs M + P  0.99
C: control group; M: miltefosine group; M + P: miltefosine plus pentoxifylline group; D: days after initiating treatment; vs: versus. *Average 

























FIGURE 2 - Methylthiazol tetrazolium absorbance. D: days after 
initiating treatment; C: control; M: miltefosine; M+P: miltefosine 
plus pentoxifylline.
diameter to indicate healing and regression of local edema and 
inﬁ ltration, even in the absence of viable parasites. Secondary 
infections and local trauma caused by the mice’s inﬁ ghting also 
cannot be discarded. 
The MTT colorimetric test indirectly assesses cellular 
mitochondrial activity and cellular viability, and is relatively 
immune to observer bias. The absorbance value increases with 
higher concentrations of formazan (a product of mitochondrial 
MTT conversion)14, and since there is no cutoff point, a direct 
comparison between the effects of the two treatments can be 
made. Although our primary goal was to determine which of 
the treatments eliminated the largest number of parasites, we 
chose not to monitor the mice until the absolute disappearance 
of parasites and lesions, since the resulting experiment would be 
burdensomely long. We found that combined treatment (M + P) 
was more effective that (M) alone, when both were compared to 
group (C), as evidenced by the lower absorbance values. Therefore, 
the combination of miltefosine and pentoxifylline provided 
greater leishmanicidal effect than miltefosine monotherapy. 
The greater effectiveness of the combination treatment 
was also observed D63, given the persistent leishmanicidal 
effect, although the sample size was suboptimal (Table 1).
The visual observation of the slides did not concretely 
contribute to the conclusions of this experiment, as visualization 
of the amastigotes on the slides was inaccurate, possible caused by 
low sensitivity or observer error. However, when the cultures were 
analyzed, we only observed a signiﬁ cant difference (p < 0.05) 
between (C) and (M). Such an inference contradicts the results our 
absorbance data, which is more accurate than direct observation. 
Therefore, various factors, such as contamination bias, sensitivity 
of cultures (30-50%), and the number of repetitions of each 
culture, should have been more adequately addressed, since they 
may have contributed to inadequate observation measurements. 
The results also could have been validated by histopathological 
evaluation, although this technique is less sensitive than 
other imaging techniques, since the cellular infiltrates can 
persist for years after treatment as previously described.
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The use of drugs with immunomodulatory effects to treat CL 
is primarily motivated by the need for alternatives to the standard 
treatment (pentavalent antimony), and has shown promising 
results in relapse cases8,15. The use of combined pentoxifylline-
miltefosine treatments could help reduced drug resistance to 
miltefosine, as well as possibly increase the efﬁ cacy of treatment8. 
Pentoxifylline has also been shown to have a nephroprotective 
effect when combined with pentavalent antimonials10.
A treatment scheme, preferably using oral administration, is 
necessary, especially in Brazil, where CL is common in the North 
and Northeast regions. Treatment is especially critical in the 
Northeast region, which is plagued by drought, extreme poverty, 
and limited access to healthcare. Considering the high rates of CL 
resistance to treatment, our results provide hope that combining 
drugs with antileishmanial and immunomodulatory effects can 
be effective in combating microbial resistance, as observed in 
the multidrug regimens used to treat leprosy and tuberculosis.
Our experiments demonstrate the superiority combined 
miltefosine and pentoxifylline in the colorimetric assay, which 
is the most accurate test for evaluating treatment efﬁ cacy. 
Therefore, we conclude that this combination may be more 
effective than the use of miltefosine alone, in the treatment of 
CL due to Leishmania amazonensis in C57Bl/6 mice. From a 
statistical point of view, there are no factors that would invalidate 
the results. However, we did not evaluate the power of the tests, 
since we were required to terminate the experiments due to 
ethical considerations. Therefore, it is necessary to perform more 
tests, using other Leishmania species prevalent in Brazil, such 
as Leishmania (Viannia) braziliensis and Leishmania (Viannia) 
guyanensis, to conﬁ rm and expand these results.
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